BMO Capital Markets restated their market perform rating on shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) in a report issued on Thursday morning. The firm currently has a $3.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $2.75.
A number of other brokerages have also recently weighed in on TTPH. Zacks Investment Research upgraded Tetraphase Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, January 12th. ValuEngine cut Tetraphase Pharmaceuticals from a sell rating to a strong sell rating in a research report on Friday, December 1st. HC Wainwright reiterated a buy rating and set a $17.00 price target on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, December 5th. BidaskClub cut Tetraphase Pharmaceuticals from a hold rating to a sell rating in a research report on Friday, February 2nd. Finally, Piper Jaffray Companies reiterated an overweight rating and set a $8.00 price target on shares of Tetraphase Pharmaceuticals in a research report on Wednesday, February 14th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company’s stock. Tetraphase Pharmaceuticals presently has a consensus rating of Hold and a consensus price target of $7.22.
Shares of Tetraphase Pharmaceuticals (TTPH) traded down $0.02 during trading on Thursday, hitting $2.90. The stock had a trading volume of 885,778 shares, compared to its average volume of 3,255,282. The firm has a market cap of $149.63, a PE ratio of -1.07 and a beta of 2.74. Tetraphase Pharmaceuticals has a fifty-two week low of $2.05 and a fifty-two week high of $9.93.
In related news, insider Jacques Dumas sold 8,750 shares of the firm’s stock in a transaction that occurred on Tuesday, January 30th. The stock was sold at an average price of $6.22, for a total value of $54,425.00. Following the sale, the insider now directly owns 8,750 shares in the company, valued at approximately $54,425. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 5.50% of the stock is owned by company insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of TTPH. SG Americas Securities LLC acquired a new stake in Tetraphase Pharmaceuticals in the 3rd quarter valued at approximately $107,000. Brighton Jones LLC acquired a new stake in Tetraphase Pharmaceuticals in the 3rd quarter valued at approximately $108,000. Voya Investment Management LLC increased its position in Tetraphase Pharmaceuticals by 17.8% in the 2nd quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 3,104 shares during the period. Ameriprise Financial Inc. acquired a new stake in Tetraphase Pharmaceuticals in the 2nd quarter valued at approximately $162,000. Finally, Cubist Systematic Strategies LLC acquired a new stake in Tetraphase Pharmaceuticals in the 3rd quarter valued at approximately $195,000. Hedge funds and other institutional investors own 58.53% of the company’s stock.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.